Celebi Solmaz, Hacimustafaoglu Mustafa, Koksal Nilgun, Ozkan Hilal, Cetinkaya Merih
Uludag University Medical Faculty, Department of Pediatrics, Division of Pediatric Infectious Diseases, Gorukle, Bursa, Turkey.
Pediatr Int. 2010 Jun;52(3):410-4. doi: 10.1111/j.1442-200X.2009.03015.x. Epub 2009 Dec 2.
The aim of the present study was to assess the efficacy and safety of colistimethate sodium therapy in multidrug-resistant nosocomial infections caused by Pseudomonas aeruginosa or Acinetobacter baumannii in neonates and children.
Pediatric patients hospitalized at the Uludag University Hospital who had nosocomial infections caused by multidrug-resistant P. aeruginosa or A. baumannii, were enrolled in the study. Colistimethate sodium at a dosage of 50-75 x 10(3) U/kg per day was given i.v. divided into three doses.
Fifteen patients received 17 courses of colistimethate sodium for the following infections: ventilator-associated pneumonia (n= 14), catheter-related sepsis (n= 1) and skin and soft-tissue infection (n= 2). The mean age of patients was 53.2 + 74.7 months (range, 8 days-15 years) and 60% were male. Mortality was 26.6%.
Colistimethate sodium appears to be safe and effective for the treatment of severe infections caused by multidrug-resistant P. aeruginosa or A. baumannii in pediatric patients.
本研究旨在评估多粘菌素甲磺酸钠治疗新生儿和儿童由铜绿假单胞菌或鲍曼不动杆菌引起的多重耐药医院感染的疗效和安全性。
纳入在乌鲁达大学医院住院的、患有由多重耐药铜绿假单胞菌或鲍曼不动杆菌引起的医院感染的儿科患者。静脉注射多粘菌素甲磺酸钠，剂量为每日50 - 75×10³U/kg，分三次给药。
15例患者接受了17个疗程的多粘菌素甲磺酸钠治疗，感染情况如下：呼吸机相关性肺炎（n = 14）、导管相关败血症（n = 1）和皮肤及软组织感染（n = 2）。患者的平均年龄为53.2 ± 74.7个月（范围8天至15岁），60%为男性。死亡率为26.6%。
多粘菌素甲磺酸钠对于治疗儿科患者由多重耐药铜绿假单胞菌或鲍曼不动杆菌引起的严重感染似乎是安全有效的。
